Simple. We focus on bringing simple solutions to healthcare providers and their patients. We pore over every detail to help make it easier for people to pursue a healthier life.
Board of Directors
Ralph Finger, MD
Ralph Finger brings 20 years of medical experience to the company. Dr. Finger received his B.A. in microbiology at the University of California, San Diego and is a graduate of the University of California Davis School of Medicine. He did his residency at the Mount Sinai program in New York in emergency medicine and is Board Certified in his specialty. He has worked as an attending physician since 1995, treating patients in several high acuity emergency departments across the country, including North Shore LIJ and Lenox Hill in New York, treating a wide variety of acute medical issues, including COPD and asthma. Dr. Finger has held leadership positions in medical practices, including most recently as the Regional Medical Director and SVP of Business Development at CityMD, one of the country's largest and fastest-growing urgent care groups. As an entrepreneur, Dr. Finger was a managing partner in several large real estate projects in New York and Telluride, Colorado. Dr. Finger is a co-founder of Convexity Scientific and the inventor of the FlypTM nebulizer. He was instrumental in assembling the team to bring the device from concept to market, and he continues to play a key role in product development.
Chief Executive Officer
Jim Daniels is one of Convexity Scientific's founders and was an active partner before being named CEO in October 2017. Prior to Convexity, he was President and CEO for High Ridge Brands, a $375 million personal care company, whose brand portfolio includes iconic brands in skin cleansing, hair and oral care. In June 2016, Clayton, Dubilier & Rice purchased High Ridge for $415 million. During his first five years at High Ridge, Mr. Daniels acquired five stand-alone brands (Zest, VO5, Rave, Coast and White Rain) as well as two companies (Newhall Laboratories and Continental Fragrances). He also divested seven non-strategic brands. In December 2016, he completed the acquisition of the Dr. Fresh Company, owners of well-known oral care brands such as Reach, Firefly, Dr. Fresh and Binaca. Before joining High Ridge, Mr. Daniels spent fifteen years at Church & Dwight, where he led the highly successful strategic business unit for Sexual Health (Trojan and Magnum brands), and held a variety of executive marketing positions across a variety of personal care divisions. He began his marketing career at Sterling Health working in the Bayer Analgesic Division. Mr. Daniels has a B.A. degree from Gordon College and an M.B.A. from Columbia Business School. In 2005, he was recognized by Advertising Age magazine as one of America’s 'Top 50 Marketers.'
Executive Managing Director
Paul Reiferson, co-founder of Convexity Scientific, brings more than 20 years of experience in entrepreneurial ventures. Prior to launching Convexity, Mr. Reiferson was the founder, Managing Principal, and Portfolio Manager for Americus Capital Advisors, a $200 million private fund specializing in event-driven value investments at all levels of the capital structure. Before that, he advised large corporate clients on strategic and financial matters at James D. Wolfensohn Incorporated. Mr. Reiferson received an M.B.A. from the Harvard Business School and a B.A. from the University of Virginia with high honors.
Kevin Crowley is Managing Director of Investments at Connecticut Innovations, where since 2006 he has led investments in over thirty companies. He currently serves as a board member for Carogen Corp., Intelligent Clearing Network Inc., Affinimark Technologies Inc., Trebel Music and others. His venture career has resulted in successful exits in multiple industries including diagnostics, therapeutics, software and cleantech. He has had three IPOs and successfully managed a $55 million bioscience venture debt fund. Additionally, Kevin serves as a founding board member of the UConn Innovation Fund and was intimately involved with the first Stem Cell fund to provide companies with research investment support.
Kevin Rakin is co-founder of HighCape Partners and brings more than 25 years of experience as an executive and investor in the life sciences industry. He most recently served as President of Shire Regenerative Medicine. Prior to joining Shire, Mr. Rakin was Chairman and Chief Executive Officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011 for $750 million. Before that, he served as an executive-in-residence at Canaan Partners. Previously, he was a Co-Founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly-traded pharmacogenomics company, until its merger with Clinical Data, Inc. in 2005. His Board memberships include Aziyo Biologics, Inc. (Chairman), Cheetah Medical, Inc. (Chairman), Cybrexa, Inc., and TELA Bio, Inc., as well as Histogenics Corp. and Collagen Matrix, Inc. He has previously served as a Board member for Ipsogen SA, Vion Pharmaceuticals, Inc., OMRIX Biopharmaceuticals, Inc., and Clinical Data, Inc. Mr. Rakin received an M.B.A. from Columbia University and B.Com and B.Com (Hons) degrees from the University of Cape Town, South Africa.
Jared Talisman is a member of the Growth Capital team of Stonehenge Capital Company. Prior to joining Stonehenge, Mr. Talisman served as a member of GrowthCap LLC’s capital-raising practice where he advised growth-stage companies on equity and structured debt investments from both institutions and family offices. Prior to GrowthCap, Mr. Talisman worked in the investment banking divisions at Lehman Brothers and North Sea Partners, where he led capital raising and strategic advisory work for both public and private companies as well as private equity firms. He began his career at Credit Suisse First Boston in the Institutional Equity Research division on two Institutional Investor All-America Research Teams. His current Board memberships include The Big Willow, Inc. Mr. Talisman received his M.B.A. from Cornell University in Ithaca, New York and his B.S. in finance from McGill University in Montreal, Quebec.
Henry Weinstein has more than eight years experience as an executive and investor in the life sciences industry. He most recently served as Vice President of Innovation and Development at Abbott Laboratories. Prior to that, he was Vice President of Strategy and Innovation at CFR Pharmaceuticals. Mr. Weinstein has a proven track record of launching over 300 products in the pharmaceutical industry in Latin America and completing more than twenty licensing deals, including biotech products and medical devices. Mr. Weinstein currently serves as a Board member of Medasense, Via Surgical and Dog Parker. He previously was a board member of BMRC, a biotech research consortium in Chile.